Eli Lilly and Co
LLY: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$586.00 | Ytz | Qckbyqst |
Eli Lilly's Cardiometabolic Portfolio and Pipeline Support Strong Growth and a Wide Moat
Business Strategy and Outlook
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds industry-leading growth potential as the company is launching several new blockbusters and patent losses are fading.